In a long-term follow-up of a phase 2 clinical trial, veterans, firefighters, and police officers with chronic, treatment-resistant PTSD reported lasting personal benefits and enhanced quality of life one year after MDMA-assisted psychotherapy. Interviews with 19 of 24 participants were analyzed using interpretative phenomenological analysis. All participants described benefits that went beyond symptom reduction, such as improved relationships and well-being. The findings suggest that qualitative methods can capture treatment effects that standard symptom scales may miss. The authors discuss limitations of the study and recommend improved qualitative research protocols for future trials.
MDMA, also called Ecstasy or Adam, is a designer drug with both stimulant and psychedelic properties that creates a unique effect sought by recreational users. Despite its recent illegality and growing evidence of neurotoxicity, interest in MDMA is expected to persist. The article examines the drug's recreational appeal and therapeutic potential, concluding that much more research is needed to understand both its possible benefits and risks.
Among New Ager seekers, social worlds shape which qualities of the MDMA experience are most valued. Unlike recreational users who see little long-term benefit, New Agers typically believe carefully planned MDMA use holds lasting spiritual or therapeutic potential. Many New Agers avoid alcohol and other drugs but are impressed with MDMA, though motivations differ: some use it as a sacramental adjunct for specific spiritual paths, others for general spiritual growth. The stark contrast between New Agers and recreational users highlights the importance of social worlds and context in understanding drug-using behavior.